Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Summer;10(2):167-82.
doi: 10.1111/j.1527-3458.2004.tb00011.x.

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

Lynne E Rueter  1 , David J Anderson, Clark A Briggs, Diana L Donnelly-Roberts, Gary A Gintant, Murali Gopalakrishnan, Nan-Horng Lin, Mark A Osinski, Glenn A Reinhart, Michael J Buckley, Ruth L Martin, Jeffrey S McDermott, Lee C Preusser, Terese R Seifert, Zhi Su, Bryan F Cox, Michael W Decker, James P Sullivan
Affiliations
Review

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

Lynne E Rueter et al. CNS Drug Rev. 2004 Summer.

Abstract

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride salt] is a selective neuronal nicotinic receptor (NNR) modulator with cognitive enhancing properties in animal models of cognitive functioning. Amongst NNR subtypes, ABT-089 shows selectivity for the cytisine binding site on the alpha4beta2 receptor subtype as compared to the alpha-bungarotoxin (alpha-BgT) binding sites on the alpha7 and alpha1beta1deltagamma receptor subtypes. In functional in vitro electrophysiological and cation flux assays, ABT-089 displays differential activity including agonism, partial agonism and antagonism depending upon the NNR subtype and assay. ABT-089 is as potent and efficacious as (-)-nicotine at evoking acetylcholine (ACh) release from hippocampal synaptosomes. Furthermore, ABT-089 is neuroprotective against excitotoxic glutamate insults, with even greater potency seen after chronic treatment. Similarly, ABT-089 is effective in models of cognitive functioning, including enhancement of baseline functioning as well as improvement of impaired cognitive functioning seen following septal lesioning and natural aging. In neuroprotective assays the compound is most potent by chronic administration. In stark contrast to the positive effects in the cognitive models, ABT-089 shows little propensity to induce adverse effects such as ataxia, hypothermia, seizures, cardiovascular or gastrointestinal side effects. Together these data suggest that ABT-089 is a NNR modulator with the potential for treating cognitive disorders with markedly limited adverse cardiovascular and gastrointestinal side effects.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arneric SP, Bannon AW, Brioni JD, et al. ABT‐089: an orally effective cholinergic channel modulator (ChCM) with cognitive enhancement and neuroprotective action In: Becker R. and Giacobini E, Eds. Alzheimer Disease: From Molecular Biology to Therapy. Boston : Birkhäuser, 1996;287–291.
    1. Ashworth‐Preece M, Jarrott B, Lawrence AJ. Nicotinic acetylcholine receptors in the rat and primate nucleus tractus solitarius and on rat and human inferior vagal (nodose) ganglia: Evidence from in vivo microdialysis and [125I] α‐bungarotoxin autoradiography. Neuroscience 1998;83:1113–1122. - PubMed
    1. Beani L, Antonelli T, Tomasini MC, Marani L, Bianchi C. The nicotinic modulation of [H‐3]D‐aspartate outflow in primary cultures of rat neocortical neurons: Effect of acute and long term nicotine treatment. Neuropharmacology 2000;39:2646–2653. - PubMed
    1. Bertrand D., Devillers‐Thiéry A, Revah F, et al. Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc Natl Acad Sci USA 1992;89:1261–1265. - PMC - PubMed
    1. Bertrand D, Galzi J‐L, Devillers‐Thiéry A, Bertrand S, Changeux J‐P. Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal α7 nicotinic receptor. Proc Natl Acad Sci USA 1993;90:6971–6975. - PMC - PubMed

LinkOut - more resources